Opinion: How CMS plans to fix a major flaw in the 340B drug discount program

Written and edited by the WorldPing NewsdeskPublished Updated Original reporting: STAT
Opinion: How CMS plans to fix a major flaw in the 340B drug discount programWorldPing
Image via STAT.

What happened

“A small, well-intended discount for safety net hospitals became a large institutional subsidy with expensive unintended consequences,” writes an HHS leader.

Key facts

  • Reported by STAT and published Thu, 08 Oct 2026 08:30:00 UTC.

Why it matters

Outbreaks, approvals and guidance changes have direct practical consequences for care, travel and public-health planning.

What to watch next

  • Case numbers and official guidance updates
  • Regulatory decisions in other countries
  • Supply, recall or access changes

Coverage timeline

When each newsroom published on this story, oldest first — all times UTC.

  1. Not all trans fats are bad, major review finds

  2. Opinion: How CMS plans to fix a major flaw in the 340B drug discount program

  3. Opinion: England and other nations are on the path toward eliminating hepatitis C. Why not the U.S.?

Sources

The original report was published by STAT. WorldPing does not claim that reporting — this page summarises and contextualises it.

Read the full report at STAT

Related WorldPing coverage

ScienceDaily
WorldPing
ScienceDaily

Not all trans fats are bad, major review finds

A large analysis of 22 studies found that the trans fats naturally present in dairy foods such as milk, butter, yogurt, and cheese do not appear to raise the risk of heart disease or type 2 diabetes.

Brief by WorldPing · Original reporting by ScienceDaily